Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Interventional, Open-label, Flexible-dose Study of Vortioxetine on Emotional Functioning in Patients With Major Depressive Disorder With Inadequate Response to SSRI/SNRI Treatment

Next Previous
Trial Profile

Interventional, Open-label, Flexible-dose Study of Vortioxetine on Emotional Functioning in Patients With Major Depressive Disorder With Inadequate Response to SSRI/SNRI Treatment

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 23 Jan 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vortioxetine (Primary)
  • Indications Major depressive disorder
  • Focus Therapeutic Use
  • Acronyms COMPLETE
  • Sponsors Lundbeck A/S

Most Recent Events

  • 15 Feb 2023 Results of an analysis assessing clinically relevant response threshold for motivation and energy inventory in patients with major depressive disorder receiving antidepressant treatment published in the Journal of Affective Disorders
  • 01 Nov 2021 Results of an analysis assessing the validaty of the Oxford Depression Questionnaire (ODQ) is a patient-reported scale for assessing emotional blunting in patients with major depressive disorder a published in the Journal of Affective Disorders
  • 15 Mar 2021 Primary endpoint (Change from baseline to Week 8 in Oxford Depression Questionnaire (ODQ) total score) has been met.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top